33 results about "Chromaffin cell" patented technology

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The present invention relates to new use of medulliadrenal chromaffin cells or opioid-peptidergic cells, in particular to their use for treating and / or relieving withdrawal syndrome resulting from drug addiction or drug abuse.

The present invention relates to new use of medulliadrenal chromaffin cells or opioid-peptidergic cells, in particular to their use for treating and / or relieving withdrawal syndrome resulting from drug addiction or drug abuse.

Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

The invention discloses a microfluidic paper chip for monitoring dopamine (DA) in cells online based on a nano-gold modified screen-printed electrode. Based on unique advantages of easiness for processing and low cost of a paper-based microfluidic chip, a novel technology for detecting the level of the dopamine released by pheochromocytoma cells (PC12 cells) is established by organically combininga flexible nano-gold modified electrochemical biosensor, so that online monitoring of the activity of the PC12 cells and Alzheimer's disease (AD) model cells is realized. According to the microfluidic paper chip, the DA releasing level of the AD model cells under the intervene of the PC12 cells, Abeta25-35 induced and constructed AD model cells, and curcumin is determined by adopting a differentpulse voltammetry; the microfluidic paper chip is successfully used for online monitoring and evaluation of normal PC12 cells and AD model cells and a novel technology can be provided for researches including medicine curative effect evaluation, new medicine development and the like of nerve-related diseases including the AD and the like.

The invention relates to a pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium, the active ingredients of the composition comprise 0.1-1% (w / w) of monosialotetrahexosyl ganglioside sodium and a rabbit meat extract containing compound amino acid with the concentration of 1-20 mg / ml, the pH value of the composition is 6-8, and the content of the compound amino acid is 1-20 mg / ml. The mass ratio of the monosialotetrahexosyl ganglioside sodium to the compound amino acid in the composition is 1: (1-10). The pharmaceutical composition disclosed by the invention has the beneficial effects of reducing the volume of encephaledema, improving ischemia and hypoxia conditions of a central nervous system, repairing and protecting nerves, remarkably improving the repair rate of pheochromocytoma damaged cells and the like.

The invention provides a preparation method of total steroidal saponin extracts of dwarf lilyturf roots, which comprises the following steps: crushing traditional Chinese medicine dwarf lilyturf roots, leaching with methanol, concentrating through vacuum filtration, separating through an ODS column, and finally separating through a silica gel chromatography open column. Based on an anti-senile dementia in-vitro screening model, experiment on rat adrenal pheochromocytoma cells proves that the total steroidal saponin extracts of dwarf lilyturf roots have activity remarkably similar to that of anerve growth factor (NGF) and can promote nerve cells to grow out and protrude. Thus, the invention is applicable to the preparation of medicaments for preventing and treating senile dementia, especially medicaments for treating Alzheimer diseases and other neurodegenerative diseases. The invention expands the pharmaceutical application of the total steroidal saponin extracts of dwarf lilyturf roots; the preparation method is convenient; the extracted product has high purity; and dwarf lilyturf roots have extensive sources and can be acquired conveniently.

The invention provides a preparation method of chest smoothing tablets. The chest smoothing tablets are prepared by performing supercritical extraction on 100 g of pseudo-ginseng, 100 g of safflower and 200 g of ligusticum wallichii serving as raw materials, so that the content of each raw material is greatly improved, and the dose is reduced. The invention also provides application of the chest smoothing tablets in preparation of a medicament for inhibiting the cell proliferation of rat adrenal pheochromocytoma PC-12.

The invention discloses a methoxyadrenaline luminescent immunoassay kit, which includes a detection system and a sample pretreatment system; wherein the detection system includes a solid-phase carrier directly or indirectly coated with an anti-methoxyephrine antibody, methoxyephrine Adrenaline-based antibody solution, avidin-linked tracer solution and calibrator; sample pretreatment system includes acidifying solution, acylating agent and alkaline buffer. The present invention has the advantage of overcoming the shortcomings and deficiencies of the existing methods for detecting methoxyepinephrine. First, acidify and acylate the methoxyepinephrine in urine or blood plasma, and use an acylating agent with biotin at one end to acylate it. The protocol, after the acylated methaphrine is recognized and reacted by the antibody, is combined with the method of avidin linked to the tracer label to accurately determine the content of methaphrine in the sample. The prepared kit has high sensitivity and precision. Using luminescent technology to automate its detection and assist in the clinical diagnosis of pheochromocytoma.

The present invention relates to a new application of chromaffin cell of adrenal medulla or opium peptide energy cell, particularly an application of curing and / or releasing withdrawal syndrome causedby addiction to drugs or drug abuse.

The invention discloses a norepinephrine luminescent immunoassay kit, which includes a detection system and a sample pretreatment system; wherein the detection system includes a solid-phase carrier directly or indirectly coated with an anti-norepinephrine antibody, norepinephrine Antibody solution, avidin-linked tracer solution and calibrator; sample pretreatment system includes enrichment material, acylating agent, methylase. The present invention first enriches, acylates, and pre-methylates norepinephrine in urine or plasma, uses cis-diol-specific affinity media to adsorb and separate norepinephrine, and adopts an acylation method in which one end is biotin The reagent acylation scheme, after the acylated and methylated norepinephrine is recognized and reacted by the antibody, is combined with the method of avidin linked to the tracer label to accurately determine the norepinephrine content in the sample. The kit of the invention has high sensitivity and precision, uses luminescence technology to realize automatic detection, and assists clinical diagnosis of pheochromocytoma.

The invention mainly elaborates application of QSER1 protein as a biomarker for diagnosis and prognosis of multiple tumors in multiple tumors and a method. The present invention describes the diagnosis of QSER1 in predicting a variety of cancers, such as liver cancer, sarcoma, kidney cancer, gastric adenocarcinoma, pheochromocytoma and parangganglioma, pancreatic cancer, breast cancer, gastric cancer, and the like. The invention further constructs shRNA (short hairpin Ribonucleic Acid) capable of specifically interfering with QSER1 gene expression, plasmids capable of interfering with QSER1 gene expression, lentiviruses capable of interfering with QSER1 gene expression and an antibody capable of specifically recognizing QSER1. The plasmid with the specific shRNA sequence and the lentivirus provided by the invention can reduce the expression level of the QSER1 gene, so that the growth of cells and the formation of cell clone can be inhibited, the apoptosis of tumor cells can be promoted, and the plasmid and the lentivirus have great significance in diagnosis and treatment of tumors. According to research results of the invention, a kit for diagnosis and prognosis prediction of various cancers can be developed, and the kit has a wide clinical application prospect.

The invention discloses a methoxynorepinephrine luminescent immunoassay kit, which includes a detection system and a sample pretreatment system; wherein the detection system includes a solid phase coated with an anti-methoxynorepinephrine antibody directly or indirectly Carrier, methoxynorepinephrine antibody solution, avidin-linked tracer solution and calibrator; sample pretreatment system includes acidifying solution, acylating agent and alkaline buffer. The present invention overcomes the shortcomings and deficiencies of the existing methoxynorepinephrine detection methods. Firstly, the methoxynorepinephrine in urine or blood plasma undergoes acidification and acylation pretreatment, and acylation with biotin at one end is adopted. Reagent acylation scheme, after the acylated methoxynorepinephrine is recognized and reacted by the antibody, it is combined with the method of avidin linked to the tracer label to accurately determine the methoxynorepinephrine in the sample content. The prepared kit has high sensitivity and precision, which can realize the automation of detection and facilitate the clinical diagnosis of pheochromocytoma.

The invention discloses an electrochemical biosensor for detecting intracellular hydrogen peroxide on line based on a paper chip in combination with a screen printing electrode. The prepared nano-platinum / multi-walled carbon nanotube material is modified on the surface of the screen printing electrode and organically combined with a self-made integrated cell culture platform-paper-based chip to manufacture a biosensor for monitoring PC12 cells (adrenal pheochromocytoma cells) that releases hydrogen peroxide on line. The biosensor is connected with an electrochemical workstation to monitor theactivities of PC12 cells and Alzheimer's disease (AD) model cells, has good specificity and high sensitivity, and provides a novel method for research on cell activity monitoring and other related fields.

The invention discloses an epinephrine luminescent immunoassay kit, which includes a detection system and a sample pretreatment system; wherein the detection system includes a solid-phase carrier directly or indirectly coated with an anti-adrenaline antibody, an adrenaline antibody solution, and avidin Connect tracer solution and calibrator; sample pretreatment system includes enrichment material, acylating agent, methylase. The present invention overcomes the shortcomings and deficiencies of the existing adrenaline detection methods. Firstly, the adrenaline in urine or plasma is enriched, acylated and methylated before treatment, and the adrenaline is adsorbed and separated by using a cis-diol-specific affinity medium. , adopt the acylation scheme of acylating agent with biotin at one end, make the acylated and methylated adrenaline recognized and reacted by the antibody, and combine with the method of avidin linked to the tracer label to accurately measure the avidin in the sample of adrenaline content. The kit of the invention has high sensitivity and precision, uses luminescence technology to realize automatic detection, and assists clinical diagnosis of pheochromocytoma.